

Appl. No. : unknown
Filed : herewith

REMARKS

The original claims correspond to the claims attached to the International Preliminary Examination Report. The claims have been amended to conform with the rules of practice before the U.S. Patent and Trademark Office. The specification has been amended to recite the International Application and priority application. The word "CLAIMS" has been deleted and substituted by "WHAT IS CLAIMED IS" so that subsequently appearing claims will be the object of a sentence as specified by M.P.E.P. section 608.01(m). As a result of this preliminary amendment, Claims 24 and 25 have been cancelled. Claims 1-19 have been amended. Accordingly, Claims 1-23 are presented for examination. Support for the amendment is found in the original claims and specification. Support for the amendment to claim 17 is found at page 28, lines 27-34 of the International Application. No new matter is being added herewith.

Abstract

An Abstract on a separate sheet is included herewith.

Conclusion

Should there be any questions concerning this application, the Examiner is invited to contact the undersigned agent at the telephone number appearing below. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Jan. 7, 2005

By:


Che Swyden Chereskin, Ph.D.
Registration No. 41,466
Agent of Record
Customer No. 20,995
(949) 760-0404

SIMMONDSIN FOR USE AS AN ANGIOGENESIS INHIBITOR

Abstract of the Disclosure

The present invention relates to the use of an active component derived from jojoba, and in particular a simmondsin, stereoisomeric forms, racemic mixtures, metabolites, pharmaceutically acceptable esters or salts thereof, or mixtures thereof for the manufacture of a medicament for inhibiting angiogenesis and for the manufacture of a medicament for treating angiogenesis-related disease. The present invention further relates to pharmaceutical compositions for inhibiting angiogenesis or for treating angiogenesis-related diseases in humans or animals and to methods for inhibiting angiogenesis and for treating angiogenesis-related diseases in humans or animals.